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Abstract: Dyslipidemias and leukocytosis are associated with cardiovascular disease and immune
disorders. Mechanistic studies have shown lipoprotein metabolism to play a significant role in
the regulation of atherosclerosis development and leukocyte activation, whereas lipid-lowering
treatments have been shown to exert beneficial anti-inflammatory and immunomodulatory effects in
clinical trials. However, the relationship between clinical markers of lipid metabolism and leukocyte
counts has not been extensively evaluated at the population level. We aimed to determine whether
clinical blood lipid measures are associated with leukocyte counts in the general U.S. population
represented in the National Health and Nutrition Examination Survey (NHANES) 1999–2004,
and whether differences exist between men and women (n = 5647). We observed a strong positive
linear trend between serum triglycerides vs. blood lymphocyte and basophil counts in both men
and women, whereas a positive trend between monocytes vs. triglycerides and lymphocytes vs.
total cholesterol and LDL-cholesterol (LDL-C) was only detected in women. Conversely, HDL-C
was inversely associated with a greater number of leukocyte subsets in men, whereas inverse trends
between HDL-C vs. lymphocytes were observed in both men and women. In multiple regression
models, a 10% increase in total cholesterol, LDL-C, and triglycerides was associated with a predicted
1.6%, 0.6%, and 1.4% increase in blood lymphocyte counts in women, respectively, whereas no
relationship was observed in men. In both men and women, a 10% increase in triglycerides was
additionally associated with higher lymphocyte, neutrophil, and basophil counts, whereas 10%
increases in HDL-cholesterol were associated with significantly lower lymphocyte, neutrophil,
eosinophil, and basophil counts in men, in addition to lower lymphocyte and monocyte counts
in women. These findings suggest that clinical lipid markers may be used to predict blood leukocyte
distributions, and that a gender-specific relationship exists between distinct classes of serum lipids
and immune cell subsets.
Keywords: serum lipids; cholesterol; leukocytes; gender; NHANES
1. Introduction
Leukocytosis, or elevation of leukocyte counts, serves as a marker of immune activation and
inflammation [1]. While commonly observed in infection [2], injury [3], hematological malignancies [4],
and allergy [5], elevated peripheral blood leukocyte counts have additionally been associated
with increased risk of cardiovascular disease (CVD) [6–8], type 2 diabetes mellitus [9], metabolic
syndrome [10–12], and nonalcoholic fatty liver disease [13,14]. Altered leukocyte profiles not only
contribute to metabolic dysfunction and inflammation, but may impair immune responses to acute
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infection and injury [15,16]. Thus, it is essential to understand the complexity of factors that impact
leukocyte activation, expansion, and inflammation in order to develop effective strategies to mitigate
metabolic and immune disorders [17].
Evidence from clinical trials and mechanistic studies suggests that there is a direct relationship
between lipid metabolism and leukocyte profiles, and that lipid-lowering interventions may provide
therapeutic potential to markers of leukocytosis and autoimmunity [18,19]. Lipoproteins can
modulate the activity of circulating blood leukocytes through interactions with immunomodulatory
proteins [20–23], as well as through mediation of cellular lipid efflux and/or loading via mechanisms
that have been elucidated within the context of lipid-laden arterial macrophages in atherosclerosis.
Greater cholesterol loading of leukocytes has been shown to enhance lipid raft formation, cellular
proliferation, and inflammatory potential, whereas promotion of cholesterol depletion, either through
HDL-mediated efflux or statin-induced suppression of endogenous cholesterol synthesis, has been
shown to suppress proliferation and pro-inflammatory immune responses [24–28]. Thus, dyslipidemias
may directly exasperate leukocytosis and altered leukocyte profiles associated with chronic metabolic
disease and immune disorders [23,29–31].
Despite promising findings from clinical and mechanistic studies, along with population studies
from China [32], Taiwan [33], and Japan [34], the relationship between serum cholesterol markers
and leukocyte profiles has not been extensively evaluated in the general U.S. adult population, or in
comparison between genders. Given that serum lipid profiles [35,36], CVD risk [37], autoimmune
disease incidence [38], and immune responses to infectious pathogens and viral vaccines vary between
men and women [39,40], research is warranted to determine whether the relationship between clinical
lipid and immune biomarkers is gender-specific to help inform diagnostic and therapeutic strategies.
Thus, our objective was to investigate the association between serum lipids and clinical leukocyte
counts in men and women from the National Health and Nutrition Examination Survey (NHANES)
1999–2004. We hypothesized that blood lipid markers can be used to predict leukocyte profiles, and that
variations in the lipid-immune relationship would be observed between men and women.
2. Experimental Section
2.1. Study Design and Population
NHANES is a comprehensive, cross-sectional, annual survey conducted in the U.S. civilian,
noninstitutionalized population by the Center for Disease Control National Center for Health Sciences.
Data from men and women ≥20 years old (n = 5647) who participated in NHANES 1999–2000,
2001–2002, and 2003–2004 were used for post-hoc analyses. Detailed information, protocols and
datasets are available online at: https://www.cdc.gov/nchs/index.htm. All NHANES protocols
were approved by the National Center for Health Statistics Research Ethics Review Board, and each
participant provided informed consent.
2.2. Survey Data and Sample Collection
Data on participant education level, race/ethnicity, statin use, and age, was collected via
survey by trained interviewers during NHANES 1999–2004 data collection cycles. Fasting blood
samples were collected in mobile medical units, and blood samples were collected for measurement
of fasting serum lipids, differential blood cell counts, and serum cotinine—a marker of tobacco
smoking [41]. Serum cotinine (ng/mL) was by determined by isotope dilution–high performance
liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry (ID
HPLC–APCI MS/MS). Waist circumference was measured using a non-flexible tape, and body weight
and height were determined to calculate body mass index (BMI).
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2.3. Fasting Serum Lipids
As stated in NHANES protocols specific to each survey cycle, total cholesterol and triglycerides
were measured directly from fasted serum samples using enzymatic assays. Serum HDL-cholesterol
(HDL-C) was measured using enzymatic assays following apolipoprotein B-containing lipoprotein
depletion by heparin-Mn2+ precipitation or direct HDL immunoassay. Total cholesterol, HDL-C,
and triglyceride concentrations were expressed as mg/dL. LDL-cholesterol (LDL-C) was calculated
using the Friedewald equation: (LDL-C) = ((total cholesterol) − (HDL-C) − (triglycerides))/5 and
expressed as mg/dL [42]. Clinically-relevant lipid categories were as follows: total cholesterol (Optimal:
<200 mg/dL; Borderline High: 200 to <240 mg/dL; High: >240 mg/dL), LDL-C (Optimal: <100 mg/dL;
Near/Above Optimal: 100 to <130 mg/dL; 130 to <160 mg/dL, 160 to <190 mg/dL, >190 mg/dL),
HDL-C (High/Optimal: Men: ≥40 mg/dL, Women: ≥50 mg/dL; Low: Men: <40 mg/dL, Women:
<50 mg/dL), and triglycerides (<150 mg/dL; 150 to <200 mg/dL; ≥200 mg/dL) [35,43].
2.4. Differential Leukocyte Counts
Complete blood counts with 5-part differential measures were performed on whole blood samples
collected during NHANES 1999–2004 cycles using a Beckman Coulter MAXM instrument. The 5-part
differential measure provided cell numbers of lymphocytes, monocytes, segmented neutrophils,
eosinophils, and basophils (103 cells/µL) that were used in post-hoc analyses.
2.5. Statistical Analysis
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NY, USA).
SAS SURVEY procedures were used to account for the complex probability sample of NHANES.
Analyses were restricted to subjects for which data was available on all outcomes and predictors.
Missing values were treated as not missing completely at random. Because of the influence of sex on
serum lipids, all analyses were performed separately for men and women. Descriptive statistics were
calculated separately for men and women in the sample and reported as counts and percentages for
categorical variables and medians and interquartile ranges for continuous variables. Comparison of
descriptive statistics between men vs. women was performed by Chi-square tests for categorical
variables, and t-tests for continuous variables. Analysis of covariance (ANCOVA) was used to
determine associations between peripheral blood leukocytes and categories of serum lipids, with blood
leukocyte levels log transformed (base e) to achieve a normal distribution of residuals. Multiple linear
regression was used to determine associations between peripheral blood leukocytes and serum lipids
on a continuous scale, with both leukocyte counts and serum lipids log transformed (base e) to achieve
a normal distribution in residuals. Because leukocyte counts were log transformed in ANCOVA
analyses, results were reported as geometric means. Since both serum lipids and leukocyte counts
were log transformed in multiple regression analyses, the slope was not easily interpretable and was
thus also presented as a percent change in blood leukocyte count for a 10% increase in serum lipid
level using the following equation:
% change in blood leukocyte count = (1.1β − 1) × 100
where β is the slope from the regression model relating serum lipids to blood leukocytes. The use of
10% does not affect the significance of the results; rather, it was chosen to demonstrate the influence
on blood leukocytes from a realistic and modest change in serum lipids. Analyses were adjusted for
age, serum cotinine, BMI, waist circumference, race/ethnicity, education, statin use, and survey cycle,
as these factors may influence lipid and leukocyte profiles [7,44–49]. A p-value less than 0.05 was
considered statistically significant.
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3. Results
3.1. Descriptive Statistics
Characteristics of the study population according to gender are presented in Table 1. The study
population included a greater proportion of women than men (52.5% vs. 47.5%). Median age and
the distribution of ethnicity groups were relatively similar between men and women. Median BMI
additionally fell within the overweight range for both genders [50]. Serum cotinine levels, a marker
of cigarette smoking [41], was higher and much more variable in men as compared to women, and a
slightly greater percentage of men reported taking statins (11.7% vs. 9.0%). Accordingly, a greater
percentage of men had total cholesterol levels <200 mg/dL (54.1% vs. 48.4%) and HDL-C within the
optimal range (73.0% vs. 65%) as compared to women. Through analysis of differential leukocyte
counts, women had a higher median level of lymphocytes and neutrophils, whereas men had higher
median levels of monocytes and eosinophils. Median and interquartile range (IQR) values for each cell
subset fell within standard reference ranges of blood leukocytes for adult men and women [51].
Table 1. Descriptive statistics of men and women in NHANES 1999–2004 (n = 5647).
Men Women p-Value
IQR IQR
Median Lower Upper Median Lower Upper
Subjects (n (%)) 2682 (47.5) 2965 (52.5)
Age, years 43 32 56 44 33 58 0.0005
Race/ethnicity (n (%)) 0.0152
Hispanic 739 (27.6) 821 (27.7)
Non-Hispanic White 1378 (51.4) 1499 (50.6)
Non-Hispanic Black 470 (17.5) 542 (18.3)
Other 95 (3.5) 103 (3.5)
BMI (kg/m2) 27.1 24.2 30.3 26.6 23.1 31.5 0.2536
Waist circumference (cm) 97.8 89.4 107.6 90.9 81.1 102.3 <0.0001
Serum cotinine (ng/mL) 0.20 0.03 119.19 0.06 0.03 1.39 <0.0001
Statin use (n (%)) 0.0049
No 2368 (88.3) 2698 (91.0)
Yes 314 (11.7) 267 (9.0)
Fasting serum lipids (mg/dL)
Total cholesterol 195.6 171.7 220.6 197.6 174.0 225.7 0.0066
LDL-cholesterol 120.5 97.7 144.0 115.2 93.9 139.9 0.0007
HDL-cholesterol 44.6 38.3 52.8 55.1 45.1 66.6 <0.0001
Triglycerides 120.7 84.4 173.7 108.4 76.6 157.6 <0.0001
Total cholesterol (n (%)) 0.1876
<200 mg/dL 1451 (54.1) 1436 (48.4)
200 to <240 mg/dL 880 (32.8) 978 (33.0)
>240 mg/dL 351 (13.1) 551 (18.6)
LDL-cholesterol (n (%)) 0.0058
<100 mg/dL 727 (27.1) 862 (29.1)
100 to <130 mg/dL 905 (33.7) 1032 (34.8)
130 to <160 mg/dL 683 (25.5) 684 (23.1)
160 to <190 mg/dL 274 (10.2) 268 (9.0)
>190 mg/dL 93 (3.5) 119 (4.0)
HDL-cholesterol (n (%)) <0.0001
M: ≥40 mg/dL; W: ≥50 mg/dL 1959 (73.0) 1926 (65.0)
M: <40 mg/dL; W: <50 mg/dL 723 (27.0) 1039 (35.0)
Triglycerides (n (%)) 0.074
<150 mg/dL 1763 (65.7) 1966 (66.3)
150 to <200 mg/dL 434 (16.2) 495 (16.7)
≥200 mg/dL 485 (18.1) 504 (17.0)
Blood leukocyte counts (103 cells/µL)
Lymphocytes 1.76 1.43 2.18 1.81 1.48 2.27 0.0003
Monocytes 0.50 0.40 0.62 0.44 0.34 0.55 <0.0001
Neutrophils 3.65 2.91 4.61 3.81 2.96 4.87 0.0064
Eosinophil 0.13 0.06 0.22 0.10 0.04 0.18 <0.0001
Basophil 0.00 0.00 0.01 0.00 0.00 0.03 0.0025
BMI: body mass index; IQR: interquartile range; M: men; NHANES: National Health and Nutrition Examination
Survey; W: women. p-values were generated from Chi-square tests and t-tests for categorical and continuous
variables, respectively.
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3.2. Associations between Serum Lipids and Leukocyte Counts in Men
To assess the relationship between serum lipids and leukocyte counts, data was analyzed by
blood leukocyte subclass and clinically-relevant cutoffs for serum lipids [35,43]. In men, lymphocyte,
monocyte, neutrophil, eosinophil, and basophil counts did not differ by levels of total cholesterol or
LDL-C (Table 2). Conversely, men with low HDL-C (<40 mg/dL) had higher lymphocyte, neutrophil,
eosinophil, and basophil counts, whereas men with elevated triglyceride levels had higher lymphocyte
counts. Associations between triglyceride levels and neutrophil and basophil counts were additionally
observed, as men with borderline high triglycerides (150 to <200 mg/dL) tended to have lower counts
of these leukocyte subsets.
Table 2. Serum lipids are differentially associated with peripheral leukocyte counts in men from
NHANES 1999–2004.
Lymphocytes Monocytes Neutrophils Eosinophils Basophils
GM 95% CI GM 95% CI GM 95% CI GM 95% CI GM 95% CI
Total cholesterol (mg/dL)
<200 1.85 1.79 1.91 0.55 0.53 0.57 3.66 3.55 3.78 1.22 1.20 1.25 1.03 1.02 1.03
200 to <240 1.84 1.78 1.90 0.54 0.52 0.56 3.79 3.63 3.96 1.23 1.20 1.26 1.03 1.02 1.04
>240 1.93 1.84 2.03 0.54 0.51 0.56 3.81 3.62 4.00 1.23 1.21 1.25 1.03 1.03 1.04
p-trend 0.17 0.13 0.72 0.20 0.92
LDL-cholesterol (mg/dL)
<100 1.86 1.80 1.93 0.56 0.53 0.58 3.78 3.64 3.92 1.23 1.21 1.25 1.03 1.03 1.04
100 to <130 1.83 1.76 1.90 0.53 0.52 0.55 3.64 3.49 3.78 1.23 1.21 1.25 1.03 1.02 1.03
130 to <160 1.85 1.78 1.93 0.54 0.52 0.57 3.73 3.59 3.88 1.22 1.19 1.25 1.03 1.02 1.03
160 to <190 1.88 1.80 1.96 0.53 0.51 0.56 3.72 3.52 3.93 1.23 1.21 1.26 1.03 1.02 1.04
>190 1.98 1.80 2.17 0.55 0.50 0.62 3.79 3.36 4.27 1.21 1.17 1.26 1.03 1.02 1.05
p-trend 0.33 0.24 0.96 0.50 0.89
HDL-cholesterol (mg/dL)
≥40 1.82 1.76 1.88 0.54 0.52 0.56 3.67 3.54 3.79 1.22 1.20 1.24 1.03 1.02 1.03
<40 1.95 1.89 2.01 0.55 0.52 0.57 3.83 3.70 3.98 1.24 1.22 1.26 1.03 1.03 1.04
p-value 0.0004 0.60 0.0114 0.05 0.0077
Triglyceride (mg/dL)
<150 1.80 1.75 1.84 0.55 0.53 0.57 3.74 3.61 3.86 1.23 1.21 1.25 1.03 1.03 1.03
150 to <200 1.93 1.85 2.01 0.56 0.53 0.58 3.66 3.53 3.78 1.22 1.20 1.25 1.03 1.02 1.03
≥200 1.97 1.89 2.05 0.53 0.51 0.56 3.74 3.50 4.01 1.22 1.19 1.24 1.03 1.02 1.04
p-trend < 0.0001 0.26 0.05 0.41 0.035
CI: confidence interval; GM: geometric mean; NHANES: National Health and Nutrition Examination Survey.
Clinical ranges for blood lipids levels are presented as mg/dL, and clinical blood leukocyte subsets are presented as
geometric means (103 cells/µL). Geometric means and tests for linear trend were adjusted for age, serum cotinine,
BMI, waist circumference, race/ethnicity, education, statin use, and survey cycle.
3.3. Associations between Serum Lipids and Leukocyte Counts in Women
When assessing the relationship between clinical lipid markers and leukocyte subset counts
in women, greater overall associations were observed as compared to men, with the exception of
HDL-C (Table 3). In women, increasing levels of total cholesterol, LDL-C, and triglycerides were
associated with sequentially higher lymphocyte counts. Conversely, increasing LDL-C was associated
with reduced monocyte and neutrophil counts—a somewhat unexpected observation given the
independent, positive associations of LDL-C, monocytes, and neutrophils with CVD risk [52–54].
Significant associations between triglyceride levels and monocytes, neutrophils, and basophils were
additionally observed, where elevated triglyceride levels corresponded to higher monocyte and
basophil counts. Similar to what was observed in men, low HDL-C (<50 mg/dL) was associated with
higher lymphocyte counts in women; however, associations between HDL-C and the other leukocyte
subsets were not significant.
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Table 3. Serum lipids are differentially associated with peripheral leukocyte counts in women from
NHANES 1999–2004.
Lymphocytes Monocytes Neutrophils Eosinophils Basophils
GM 95% CI GM 95% CI GM 95% CI GM 95% CI GM 95% CI
Total cholesterol (mg/dL)
<200 1.94 1.87 2.01 0.50 0.49 0.51 3.77 3.65 3.89 1.19 1.17 1.20 1.03 1.02 1.03
200 to <240 2.00 1.94 2.07 0.48 0.46 0.50 4.11 3.93 4.30 1.18 1.16 1.20 1.03 1.03 1.04
>240 2.08 1.20 2.17 0.49 0.46 0.52 4.21 3.97 4.46 1.20 1.18 1.22 1.04 1.04 1.05
p-trend 0.0008 0.14 0.35 0.75 0.18
LDL-cholesterol (mg/dL)
<100 1.93 1.86 1.21 0.51 0.49 0.52 4.01 3.84 4.18 1.19 1.18 1.20 1.03 1.03 1.04
100 to <130 1.99 1.92 2.06 0.49 0.47 0.51 3.90 3.75 4.05 1.18 1.17 1.20 1.03 1.03 1.04
130 to <160 2.00 1.92 2.09 0.48 0.46 0.50 3.83 3.64 4.04 1.19 1.17 1.20 1.03 1.02 1.04
160 to <190 2.06 1.93 2.20 0.49 0.46 0.52 3.86 3.56 4.18 1.17 1.15 1.19 1.04 1.03 1.04
>190 2.09 1.95 2.23 0.46 0.42 0.52 3.71 3.40 4.06 1.22 1.15 1.28 1.04 1.02 1.05
p-trend 0.0045 0.0089 0.046 0.92 0.51
HDL-cholesterol (mg/dL)
≥50 1.93 1.88 1.99 0.49 0.47 0.51 3.89 3.75 4.03 1.18 1.17 1.20 1.03 1.03 1.04
<50 2.03 1.95 2.12 0.50 0.41 0.51 3.97 3.81 4.15 1.20 1.18 1.21 1.03 1.03 1.04
p-trend 0.0079 0.36 0.25 0.08 0.29
Triglycerides (mg/dL)
<150 1.88 1.82 1.93 0.48 0.46 0.50 3.97 3.84 4.10 1.19 1.18 1.20 1.03 1.03 1.04
150 to <200 2.06 1.98 2.14 0.50 0.48 0.52 3.84 3.66 4.02 1.18 1.17 1.20 1.03 1.03 1.04
≥200 2.18 2.06 2.30 0.53 0.51 0.56 3.91 3.67 4.18 1.19 1.16 1.21 1.04 1.03 1.04
p-trend <0.0001 <0.0001 <0.0001 0.41 0.0002
CI: confidence interval; GM: geometric mean; NHANES: National Health and Nutrition Examination Survey.
Clinical ranges for blood lipids levels are presented as mg/dL, and clinical blood leukocyte subsets are presented as
geometric means (103 cells/µL). Geometric means and tests for linear trend were adjusted for age, serum cotinine,
BMI, waist circumference, race/ethnicity, education, statin use, and survey cycle.
3.4. Total Cholesterol Predicts Leukocyte Counts in Women, But Not Men
Given the differential associations between blood lipids and leukocyte subsets between men and
women, we next set out to determine whether blood lipids could be used to predict leukocyte counts
as a way to further elucidate a potential direct relationship between lipid metabolism and immunity.
Using both adjusted and unadjusted multiple regression models, total cholesterol (Table 4) levels were
not able to significantly predict any of the leukocyte subset counts in men. Conversely, total cholesterol
significantly predicted lymphocyte counts in women (Table 4), an observation that was strengthened
after adjusting for age, serum cotinine, BMI, waist circumference, race/ethnicity, education, statin use,
and NHANES survey cycle. In the adjusted model, a 1.6% increase in lymphocyte counts (103 cells/µL)
could be predicted for every 10% increase in total cholesterol level (mg/dL). Total cholesterol was not
able to significantly predict monocytes, neutrophils, eosinophils, or basophils in women using the
adjusted model.
3.5. LDL-Cholesterol Predicts Leukocyte Counts in Women, But Not Men
Similar to that observed for total cholesterol, LDL-C did not predict leukocyte counts in men
using adjusted and unadjusted multiple regression models (Table 5). However, LDL-C served as a
significant predictor of lymphocyte, monocyte, and neutrophil counts in women. In the adjusted
model, every 10% increase in LDL-C was associated with a 0.6% increase in lymphocytes, as well as
a 0.7% and 0.6% decrease in monocyte and neutrophil counts, respectively. These findings suggest
that LDL-C may have a greater impact on global immune profiles, beyond total cholesterol. Predictive
associations were not observed between LDL-C and eosinophil or basophil counts.
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Table 4. Multiple regression models of serum total cholesterol levels predicting changes in peripheral
blood leukocyte counts between men and women in NHANES 1999–2004.
Men Women
Cell Count Model β SE % ∆ p β SE % ∆ p
Lymphocytes unadjusted 0.045 0.046 0.4 0.33 0.083 0.035 0.8 <0.05
adjusted 0.081 0.044 0.8 0.07 0.168 0.036 1.6 <0.0001
Monocytes unadjusted −0.038 0.037 −0.4 0.30 0.002 0.037 0.0 0.95
adjusted −0.064 0.036 −0.6 0.08 −0.079 0.040 −0.7 0.06
Neutrophils unadjusted 0.051 0.045 0.5 0.27 −0.038 0.045 −0.4 0.40
adjusted 0.002 0.042 0.0 0.97 −0.035 0.047 −0.3 0.46
Eosinophils unadjusted −0.012 0.017 −0.1 0.49 −0.006 0.015 −0.1 0.67
adjusted −0.014 0.017 −0.1 0.41 −0.012 0.017 −0.1 0.49
Basophils unadjusted 0.009 0.006 0.1 0.18 0.013 0.006 0.1 <0.05
adjusted 0.006 0.006 0.1 0.34 0.006 0.005 0.1 0.27
β: slope; SE: standard error; p: p-value. % ∆ = the predicted % change in blood leukocyte count (103 cells/µL) for
a 10% increase in total cholesterol level (mg/dL). Adjusted model is adjusted for age, serum cotinine, BMI, waist
circumference, race/ethnicity, education, statin use, and survey cycle. To best approximate linearity, both predictor
and outcome were log transformed (base e); thus slope and standard errors are on log scale.
Table 5. Multiple regression models of serum LDL-C predicting changes in peripheral blood leukocyte
counts between men and women in NHANES 1999–2004.
Men Women
Cell Count Model β SE % ∆ p β SE % ∆ p
Lymphocytes unadjusted 0.025 0.032 0.2 0.43 0.063 0.026 0.6 <0.05
adjusted 0.037 0.031 0.3 0.24 0.063 0.026 0.6 <0.05
Monocytes unadjusted −0.019 0.026 −0.2 0.47 −0.023 0.023 −0.2 0.33
adjusted −0.035 0.026 −0.3 0.19 −0.075 0.023 −0.7 <0.01
Neutrophils unadjusted 0.017 0.031 0.2 0.59 −0.036 0.030 −0.3 0.25
adjusted −0.008 0.029 −0.1 0.80 −0.065 0.031 −0.6 <0.05
Eosinophils unadjusted −0.007 0.011 −0.1 0.50 −0.002 0.010 0.0 0.85
adjusted −0.006 0.011 −0.1 0.61 −0.007 0.012 −0.1 0.56
Basophils unadjusted 0.004 0.004 0.0 0.35 0.004 0.003 0.0 0.28
adjusted 0.003 0.004 0.0 0.48 −0.002 0.003 0.0 0.56
β: slope; SE: standard error; p: p-value. % ∆ = the predicted % change in blood leukocyte count (103 cells/µL) for a
10% increase in LDL-C level (mg/dL). Adjusted model is adjusted for age, serum cotinine, BMI, waist circumference,
race/ethnicity, education, statin use, and survey cycle. To best approximate linearity, both predictor and outcome
were log transformed (base e); thus slope and standard errors are on log scale.
3.6. HDL-Cholesterol Predicts Leukocyte Counts in both Men and Women
Despite the greater associations between immune profiles and serum lipids observed in women
described above, HDL-C served as a significant predictor of each leukocyte subset in both men and
women in the unadjusted model (Table 6). In contrast to the positive associations observed between
total cholesterol, LDL-C, and immune profiles, HDL-C was inversely associated with all predicted
leukocyte levels. Interestingly, certain associations were lost after adjusting for covariates, which varied
by gender. In the adjusted model, a 10% increase in HDL-C was associated with a 1.6% and 0.9%
decrease in lymphocytes in men and women, respectively. However, predicted changes in neutrophils
(−1.1%), eosinophils (−0.3%), and basophils (−0.1%) were only observed in men for every 10%
increase in HDL-C, whereas predicted changes in monocytes (−0.6%) were solely observed in women.
These findings correspond to the greater associations between HDL-C and leukocyte counts observed
in men above (Table 2) and suggest that changes in HDL-C may have a greater magnitude and range
of impact on immune profiles in men, as compared to women.
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Table 6. Multiple regression models of serum HDL-cholesterol predicting changes in peripheral blood
leukocyte counts between men and women in NHANES 1999–2004.
Men Women
Cell Count Model β SE % ∆ p β SE % ∆ p
Lymphocytes unadjusted −0.204 0.035 −1.9 <0.0001 −0.234 0.027 −2.2 <0.0001
adjusted −0.171 0.032 −1.6 <0.0001 −0.098 0.033 −0.9 <0.01
Monocytes unadjusted −0.067 0.031 −0.6 <0.05 −0.101 0.021 −1.0 <0.0001
adjusted −0.018 0.033 −0.2 0.59 −0.059 0.022 −0.6 <0.01
Neutrophils unadjusted −0.192 0.032 −1.8 <0.0001 −0.205 0.031 −1.9 <0.0001
adjusted −0.118 0.031 −1.1 <0.001 −0.049 0.035 −0.5 0.17
Eosinophils unadjusted −0.035 0.012 −0.3 <0.01 −0.029 0.009 −0.3 <0.01
adjusted −0.032 0.012 −0.3 <0.05 −0.019 0.010 −0.2 0.06
Basophils unadjusted −0.014 0.003 −0.1 <0.001 −0.009 0.004 −0.1 <0.05
adjusted −0.011 0.004 −0.1 <0.01 −0.002 0.004 0.0 0.64
β: slope; SE: standard error; p: p-value. % ∆ = the predicted % change in blood leukocyte count (103 cells/µL) for a
10% increase in LDL-C level (mg/dL). Adjusted model is adjusted for age, serum cotinine, BMI, waist circumference,
race/ethnicity, education, statin use, and survey cycle. To best approximate linearity, both predictor and outcome
were log transformed (base e); thus slope and standard errors are on log scale.
3.7. Serum Triglycerides Levels Predict Leukocyte Counts in Both Men and Women
In addition to blood cholesterol markers, triglycerides levels were found to predict leukocyte
subsets through positive associations, with relatively minimal variability observed between men and
women (Table 7). In adjusted models, a 10% increase in triglyceride levels was associated with a 1.1%
and 1.4% increase in lymphocytes in men and women, respectively. Similar trends were observed for
neutrophils and basophils, where a 10% increase in triglycerides corresponded to a predicted 0.7% and
0.1% increase in these cell subsets in men, respectively, as well as a 1.2% and 0.1% increase in women.
Predicted changes in monocytes (0.6%) were only observed in women, whereas triglycerides were not
able to predict changes in eosinophils in men or women.
Table 7. Multiple regression models of serum triglycerides predicting changes in peripheral blood
leukocyte counts between men and women in NHANES 1999–2004.
Men Women
Cell Count Model β SE % ∆ p β SE % ∆ p
Lymphocytes unadjusted 0.097 0.012 0.9 <0.0001 0.135 0.014 1.3 <0.0001
adjusted 0.112 0.013 1.1 <0.0001 0.145 0.015 1.4 <0.0001
Monocytes unadjusted 0.025 0.013 0.2 0.06 0.100 0.017 1.0 <0.0001
adjusted 0.000 0.014 0.0 1.00 0.067 0.019 0.6 <0.001
Neutrophils unadjusted 0.123 0.018 1.2 <0.0001 0.161 0.017 1.6 <0.0001
adjusted 0.075 0.020 0.7 <0.001 0.124 0.020 1.2 <0.0001
Eosinophils unadjusted 0.016 0.006 0.2 <0.05 0.012 0.005 0.1 <0.05
adjusted 0.010 0.006 0.1 0.10 0.006 0.005 0.1 0.21
Basophils unadjusted 0.010 0.002 0.1 <0.0001 0.013 0.002 0.1 <0.0001
adjusted 0.008 0.002 0.1 <0.01 0.011 0.002 0.1 <0.0001
β: slope; SE: standard error; p: p-value. % ∆ = the predicted % change in blood leukocyte count (103 cells/µL) for a
10% increase in LDL-C level (mg/dL). Adjusted model is adjusted for age, serum cotinine, BMI, waist circumference,
race/ethnicity, education, statin use, and survey cycle. To best approximate linearity, both predictor and outcome
were log transformed (base e); thus slope and standard errors are on log scale.
4. Discussion
Clinical and mechanistic studies have demonstrated that lipid metabolism plays an important
role in leukocyte activity, which may have significant gender-specific implications for CVD, metabolic
dysfunction, and immune disorders [17,19,26,29,38,40,55]. In this study of 5647 men and women
from NHANES 1999–2004, we have demonstrated that there are significant relationships between
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clinical lipid markers and leukocyte counts in the general U.S. population, and that clinical lipid
markers differentially predict specific leukocyte subsets to varying degrees in men and women.
Our findings suggest that hypertriglyceridemia may impact immune profiles in both men and women,
whereas hypercholesterolemia may only affect lymphocyte profiles in women. Further, increases in
HDL-C may differentially affect immune profiles in men and women, leading to variable immune
outcomes. To our knowledge, our study is the first to evaluate the lipid–leukocyte relationship
in NHANES.
Differences in both lipid and leukocyte profiles between men and women have previously been
reported [56,57], suggesting that the gender-specific lipid-immune relationships we observed may be
attributable to innate variability in lipid metabolism and immune cell behavior. Clinical guidelines for
optimal HDL-C levels are distinct for men (>40 mg/dL) and women (>50 mg/dL) [35,36], and men
often present with higher total cholesterol, LDL-C, and triglycerides as compared to premenopausal
women, although these trends are equalized or reversed in post-menopausal women [56,58,59].
Gender-specific patterns in lipid profiles are in line with observed differences in CVD risk for men vs.
women at different life stages, and some studies suggest that there are gender differences in the efficacy
of statin therapy [37,60,61]. Women also have greater risk for autoimmune disorders, viral infection,
and adverse responses to vaccines, while exhibiting enhanced humoral and cell-mediated responses as
compared to men [38–40,62]. Variability in lipid and immune profiles between men and women has
not been solely attributed to hormonal differences, but may be further impacted by differences in body
fat distribution and cholesterol, triglyceride, and fatty acid metabolism [58,63–65]. Thus, the complex
dynamics of lipid metabolism and immune function between genders may explain the variability in
relationships between specific clinical biomarkers.
Lipoproteins can directly impact leukocyte profiles and activity through modulation of cellular
cholesterol flux, lipid raft organization, sequestration of pathogenic stimuli, and provision of
immunomodulatory proteins [19,22]. Cellular cholesterol loading—either through enhanced LDL
uptake or deletion of HDL-associated lipid efflux transporters such as ABCA1 or ABCG1—has
been shown to enhance the proliferative and inflammatory potential of lymphocytes and
macrophages [24,26,66]. However, mechanisms of lipid metabolism and expression profiles differ
in monocytes [67], and hypercholesterolemia has been shown to impair neutrophil function [68].
Similar trends were observed on our study, as increased total cholesterol and LDL-C levels were
associated with greater predicted levels of lymphocytes in women. Conversely, greater LDL-C
was associated with lower predicted monocyte and neutrophil levels in women, whereas no
associations between total cholesterol, LDL-C, or any leukocyte subset were observed in men.
Thus, hypercholesterolemia—particularly due to elevated LDL levels—may promote selective,
and gender-specific expansion lymphocytes and altered, and potentially impaired, monocyte and
neutrophil profiles. These observations may be due to gender-specific variability in lipid metabolism
and immune responsiveness, as described above [56,57,64].
In contrast to cholesterol loading, HDL-mediated efflux has been shown to promote cholesterol
depletion of leukocytes, leading to reduced formation of membrane lipid rafts, suppressed
toll-like receptor 4-mediated inflammatory signaling, and a lower proliferative capacity of
lymphocytes [24–26,69]. Further, lipoproteins—particularly HDL—can sequester bacterial pathogens
such as lipopolysaccharide and lipoteichoic acid, thereby preventing leukocyte activation and
improving clinical outcomes of sepsis [19,70–74]. HDL and apolipoprotein A 1 (apoA1) have
additionally been shown to inhibit neutrophil activation, recruitment, and adhesion [75]. Our study
revealed similar associations, in that a 10% increase in HDL-C predicted lower lymphocyte, neutrophil,
eosinophil, and basophil counts in men. In contrast, after adjusting for potential confounding
factors such as age, smoking, BMI, central adiposity (waist circumference), race/ethnicity, and statin
use [7,44–49], HDL-C levels were only able to predict lymphocyte and monocyte counts in women.
Regardless of gender, each lipid marker was inversely associated with HDL-C levels, suggesting that
cholesterol- and immune-modulating properties of HDL universally suppress indices of leukocytosis
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in monocytes and lymphocyte subsets, and that HDL appears to have limited impacts on granulocyte
populations in women. Interestingly, differences in HDL particle size profiles and cholesterol efflux
capacity have been observed between genders, with women exhibiting a greater degree of larger HDL2-
and scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux, whereas men exhibit greater
preβ HDL- and ATP-binding cassette transporter A1 (ABCA1)-mediated efflux [76]. Thus, the variable
relationships between HDL-C and differential cell subsets may represent differences in HDL particle
size profiles and leukocyte cholesterol efflux patterns between men and women.
In addition to observing unique relationships between serum cholesterol and immune markers
between men and women, we found significant linear trends between triglycerides vs. lymphocytes,
neutrophils, and basophils in both men and women, whereas positive linear trends between
triglycerides vs. monocytes were only observed in women. Accordingly, a 10% increase in triglycerides
was associated with higher predicted lymphocyte, neutrophil, and basophil counts in both men and
women, as well as greater predicted monocyte counts in women. Elevated serum triglycerides
are indicative of elevated hepatic lipogenesis, very low-density lipoprotein (VLDL) production,
and reduced systemic lipolysis [77,78]. Hypertriglyceridemia is often associated with physiological
conditions that promote immune activation, including metabolic dysfunction, lipid deposition in
metabolic and lymphoid tissues, and direct activation of leukocyte populations by fatty acids [17,79–81].
Given the universal positive associations between serum triglycerides and leukocyte subsets, with little
variability between men and women, our findings suggest that hypertriglyceridemia may promote
leukocytosis in a relatively gender-independent manner.
Our study is one of a limited number of reports that has evaluated the direct, predictive
relationship between lipid markers and leukocyte profiles in large-scale populations—particularly in
the general U.S. population. In hypertensive male and female patients from the China Stroke Primary
Prevention Trial cohort, Liu et al. [32] found that serum total cholesterol, LDL-C, and triglyceride levels
were positively associated with total leukocyte, lymphocyte, and neutrophil counts, whereas HDL-C
was inversely associated with leukocyte counts. In 3282 Taiwanese subjects participating in a standard
hospital health screening program, hyperlipidemia was positively associated with total leukocyte
counts, as well as each differential cell counts aside from eosinophils [33]. In evaluating immune
associations by lipid category, hypertriglyceridemia had a stronger positive association with levels of
each differential leukocyte subset. Conversely, hypercholesterolemia was positively associated with
lymphocyte, neutrophil, and basophil counts, yet inversely associated with monocyte counts [33].
Together, these population studies support findings from our study and mechanistic trials, in that
lipid profiles indicative of lipid loading promote selective leukocytosis, whereas HDL-mediated
pathways are associated with suppressed leukocytosis [19,24,25,69]. However, the majority of
previous studies have not elucidated gender-specific relationships between markers of immunity
and serum lipids [32,33], which we found to be significantly variable. In line with our study,
Oda et al. [34] observed greater associations between hypertriglyceridemia, hypo-HDL cholesterolemia,
and hyper-LDL cholesterolemia vs. differential leukocyte counts in Japanese men participating in
general health screenings, as compared to women. While we observed stronger overall lipid-leukocyte
associations in women—with the exception of HDL-C—this report supports our conclusions that
complex, gender-specific associations between serum lipid markers and leukocyte counts exist at the
population level.
5. Conclusions
The predictive, diagnostic, and therapeutic significance of our findings warrants further
investigation. Global and/or selective elevation of leukocyte populations may be indicative of CVD [6],
metabolic dysfunction [9,10], infection [2], injury [3], or allergy [5]. While a limitation of our study was
that we were unable to account for confounding immune-modulating factors (e.g., infection and allergy
status, steroid usage), we clearly demonstrate that serum lipid levels impact and predict leukocyte
profiles, suggesting that lipid-modulating therapies—such as diet, weight loss, or statins—may regulate
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leukocyte expansion and behavior [17,19,55,82–84]. Importantly, the efficacy of targeting serum lipids
to promote immune health may be gender specific, calling for greater examination of immune outcomes
and gender effects in clinical lipid trials.
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